PHAT
Phathom Pharmaceuticals IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$903.63M
P/E Ratio
—
EPS
$-2.09
Beta
0.57
52W High
$18.31
52W Low
$3.92
50-Day MA
$11.75
200-Day MA
$12.83
Dividend Yield
—
Profit Margin
-76.80%
Forward P/E
—
PEG Ratio
—
About Phathom Pharmaceuticals Inc
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company is headquartered in Florham Park, New Jersey.
Fundamentals
| Revenue (TTM) | $204.89M |
| Gross Profit (TTM) | $174.02M |
| EBITDA | $-96.03M |
| Operating Margin | -26.60% |
| Return on Equity | -3489.00% |
| Return on Assets | -20.20% |
| Revenue/Share (TTM) | $2.72 |
| Book Value | $-4.24 |
| Price-to-Book | 25.37 |
| Price-to-Sales (TTM) | 4.41 |
| EV/Revenue | 4.341 |
| EV/EBITDA | -2.20 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 104.40% |
| Shares Outstanding | $79.76M |
| Float | $60.43M |
| % Insiders | 4.61% |
| % Institutions | 88.46% |
Historical Volatility
HV 10-Day
64.87%
HV 20-Day
64.73%
HV 30-Day
64.28%
HV 60-Day
63.06%
HV Rank
—
Volatility is currently expanding
Analyst Ratings
Consensus ($23.70 target)
2
Strong Buy7
Buy1
HoldMore HEALTHCARE Stocks
Data last updated: 5/25/2026